KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113.

Koh Fukushi, Hiroshi Imaoka, Masafumi Ikeda, Junki Mizusawa, Chigusa Morizane, Takuji Okusaka, Satoshi Kobayashi, Naoki Sasahira, Satoshi Shimizu, Kentaro Yamazaki, Naohiro Okano, Haruo Miwa, Kazuo Hara, Sohei Satoi, Keiji Sano, Kenji Sakai, Rie Sugimoto, Kazuyoshi Nakamura, Takeshi Terashima, Masato Ozaka, Makoto Ueno, JCOG Hepatobiliary and Pancreatic Oncology Group

Jpn J Clin Oncol 55(4) 355-361

PMID39775866
PMCIDPMC11973634
DOI10.1093/jjco/hyae188
发表日期2025-01-08
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer. METHODS: The objective of this post-hoc analysis was to assess the inter-institutional heterogeneity in the overall survival and progression-free survival of patients with advanced biliary tract cancer treated with first-line chemotherapy in the JCOG1113 trial. The heterogeneity in the overall survival and progression-free survival was assessed according to three factors: hospital volume, experience in medical oncology and experience in biliary intervention. A total of 300 advanced biliary tract cancer patients were analyzed. There were no statistically significant trends observed between hospital volume, experience in medical oncology, or experience in biliary intervention and overall survival (hospital volume: adjusted trend P value = 0.6796; experience in medical oncology: adjusted trend P value = 0.4092; experience in biliary intervention: adjusted trend P value = 0.6112). Similarly, no statistically significant trends were observed between these factors and progression-free survival (hospital volume: adjusted trend P value = 0.3000; experience in medical oncology: adjusted trend P value = 0.1108; experience in biliary intervention: adjusted trend P value = 0.2898). CONCLUSIONS: This study revealed no inter-institutional heterogeneity in the overall survival and progression-free survival in the JCOG1113 study population of advanced biliary tract cancer patients.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Kaplan–Meier curves for both overall survival (OS) (A) and progression-free survival (PFS) (B) in eligible advanced biliary tract cancer (BTC) patients treated with GS or GC.

A

Overall survival

Figure 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Progression-free survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Study flow chart.
非 KM Figure
Figure 3Kaplan–Meier curves for OS according to the hospital volume (A), experience in medical oncology (B) and experience in biliary intervention (C).
非 KM Figure
Figure 4Kaplan–Meier curves for PFS according to the hospital volume (A), experience in medical oncology (B) and experience in biliary intervention (C).
非 KM Figure